AMG-458 is a potent, selective and orally bioavailable c-Met inhibitor, with Ki values of 1.2 nM and 2.0 nM for human and mouse c-Met, respectively.
性状
Solid
IC50 & Target[1][2]
VEGDR2
4100 nM (Ki)
体内研究(In Vivo)
AMG-458 (orally, 30, 100 mg/kg) significantly inhibits tumor growth in the NIH3T3/TPR-Met and U-87 MG xenograft models with no adverse effect on body weight.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
NIH-3T3/TPR-Met model and U-87 MG human glioblastoma xenograft model.
Dosage:
10, 30, 100 mg/kg.
Administration:
Orally q.d. or b.i.d.
Result:
With an ED50 of ~12 mg/kg and an ED90 of ~ 34 mg/kg in NIH-3T3/TPR-Met model.
With an ED50 of ~16 mg/kg and an ED90 of ~ 59 mg/kg in U-87 MG human glioblastoma xenograft model.
Significantly inhibited tumor growth at 30 and 100 mg/kg q.d. and 30 mg/kg b.i.d. without adverse effect on body weight.
Animal Model:
Balb/c mouse and SD rat.
Dosage:
1 mg/kg (Pharmacokinetic Analysis).
Administration:
IV dose: 1 mg/kg (20% Captisol with pH adjusted to 3.5 using methanesulfonic acid).
Result:
Exhibited CL ((L/h)/kg) values of 0.16 and 0.73, Vss (L/kg) values of 0.31 and 0.62, t1/2 (h) values of 1.3 and 1.0 in mouse and rat, respectively.